NanoViricides Inc (NNVC)

NanoViricides Inc (NNVC) requires closer examination – US Post News - US Post News

US Post News

StockNews.com Initiates Coverage on NanoViricides (NYSE:NNVC) - Defense World

Defense World

NNVC’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle

The InvestChronicle

NanoViricides Has Filed its Quarterly Report | Ap | thederrick.com - Oil City Derrick

Oil City Derrick

NanoViricides Has Filed its Quarterly Report - Yahoo Finance

Yahoo Finance

NanoViricides shares gain as new data shows lead drug asset's strong activity against RSV - Proactive Investors USA

Proactive Investors USA

A Novel Broad-Spectrum Antiviral with Activity Against RSV - Oil City Derrick

Oil City Derrick

A Novel Broad-Spectrum Antiviral with Activity Against RSV - Yahoo Finance

Yahoo Finance

NanoViricides CEO discusses NV-387's broad-spectrum antiviral potential - Proactive Investors USA

Proactive Investors USA

NanoViricides to showcase lead drug asset's progress at global conference - Proactive Investors USA

Proactive Investors USA

NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City - Miami Herald

Miami Herald

NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City - Oil City Derrick

Oil City Derrick

NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City - Miami Herald

Miami Herald

NanoViricides Reports Research with NV-387 Showing Promising Results Against Multiple Viruses - Proactive Investors Australia

Proactive Investors Australia

Check Out NanoViricides Inc (NNVC)'s Trade Data Rather Than the Analysts' Views – Sete News - SETE News

SETE News

NanoViricides (NYSE:NNVC) Now Covered by StockNews.com - Defense World

Defense World

NanoViricides says lead asset shows antiviral activity against Smallpox and Mpox - Proactive Investors UK

Proactive Investors UK

NanoViricides Inc (NNVC) deserves closer scrutiny – US Post News - US Post News

US Post News

A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox - Sacramento Bee

Sacramento Bee

A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox - Oil City Derrick

Oil City Derrick

A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox - Miami Herald

Miami Herald

NanoViricides drug asset shows 'superior antiviral effects' against Influenza A - Investing.com Canada

Investing.com Canada

NanoViricides drug asset shows 'superior antiviral effects' against Influenza A - Proactive Investors USA

Proactive Investors USA

A Novel Broad-Spectrum Antiviral with Activity Against Influenza A - Oil City Derrick

Oil City Derrick

A Novel Broad-Spectrum Antiviral with Activity Against Influenza A - Yahoo Finance

Yahoo Finance

StockNews.com Initiates Coverage on NanoViricides (NYSE:NNVC) - Defense World

Defense World

NanoViricides completes Phase 1 trial for respiratory viral infection candidate - Proactive Investors UK

Proactive Investors UK

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon - Charlotte Observer

Charlotte Observer

NanoViricides (NYSE:NNVC) Earns Sell Rating from Analysts at StockNews.com - Defense World

Defense World

NanoViricides (NASDAQ: NNVC) Hits Key Milestones For Its Virus-Fighting Drug Candidate NV-387 In 2023; Mo - Benzinga

Benzinga

NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed ... - Yahoo Finance

Yahoo Finance

NanoViricides: Fiscal Q2 Earnings Snapshot - Quartz

Quartz

Nanoviricides: Phase Ia/b healthy participant dosing completed; pox virus data - Proactive Investors UK

Proactive Investors UK

NanoViricides' Phase 1 Broad-Spectrum Antiviral Highly Effective for Mpox and Smallpox - Global Biodefense

Global Biodefense

Nanoviricides: COVID-19 therapy trial underway, RSV trial to follow - Proactive Investors Australia

Proactive Investors Australia

NanoViricides commences clinical trials for its broad-spectrum antiviral drug NV-CoV-2 - Proactive Investors UK

Proactive Investors UK

NanoViricides is leveraging its unique nanoviricide platform technology to create first-in-class drugs against viruses - Proactive Investors USA

Proactive Investors USA

NNVC: NanoViricides Technology Ready to Enter the Clinic - Yahoo Finance

Yahoo Finance

Nanoviricides completes IND-enabling work for NV-CoV-2 - BioWorld Online

BioWorld Online

The 7 Best Nanotechnology Stocks To Buy For %currentmonth% %currentyear% - The Stock Dork

The Stock Dork

Booster Shots Might Not Be Enough to Beat Omicron, According to Some Nanotech Experts - Nanoviricides (AM - Benzinga

Benzinga

NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID-19 Drug Development - PR Newswire

PR Newswire

Nanomedicine Company Makes "Nanomachines" that Attack Viruses - Yahoo Finance

Yahoo Finance

Dr. Anil R. Diwan Leads NanoViricides In Fight Against COVID-19 - Forbes India

Forbes India

Cashing in on coronavirus: Small biopharma company NanoViricides sees stock soar on treatment claims - CNBC

CNBC

Covid-Linked Stocks Rally on Trump's 'Surprise' Hint, Day Trades - Bloomberg

Bloomberg

NanoViricides Will Return To $3-$5 As Soon As The Coronavirus Newsflow Fades (NYSE:NNVC) - Seeking Alpha

Seeking Alpha

Company News For Jan 28, 2020 - Yahoo News UK

Yahoo News UK

Inovio’s stock soars after receiving grant to develop coronavirus vaccine - MarketWatch

MarketWatch

18 Medical Stocks To Watch Amid The Coronavirus Outbreak - Inovio Pharmaceuticals (NASDAQ:INO), Novavax ( - Benzinga

Benzinga